EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024)

EyePoint (EYPT) posted Non-Current Deffered Revenue of $10.9 million for Q4 2024, down 3.39% sequentially from $11.2 million in Q3 2024, and down 47.55% YoY from $20.7 million in Q1 2024.

Analysis

EyePoint (EYPT) Non-Current Deffered Revenue (2011 - 2024) Analysis & Trends

EyePoint has reported Non-Current Deffered Revenue for 12 years, with the latest figure at $10.9 million in Q4 2024.

  • Quarterly Non-Current Deffered Revenue fell 47.55% year-over-year to $10.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $10.9 million (down 47.55% YoY) and the FY2024 annual result came in at $10.9 million, down 47.55% from the prior year.
  • Non-Current Deffered Revenue retreated to $10.9 million in Q4 2024 per EYPT's latest filing, from $11.2 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $44.0 million in Q2 2023 and troughed at $10.9 million in Q4 2024.
  • A 5-year average of $16.9 million and a median of $14.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue surged 212.87% in 2023, then sank 73.47% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $15.6 million in 2020, then fell by 6.76% to $14.6 million in 2021, then dropped by 6.89% to $13.6 million in 2022, then soared by 52.63% to $20.7 million in 2023, then sank by 47.55% to $10.9 million in 2024.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $10.9 million, $11.2 million, and $11.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 10.85 Mn
Sep 30, 2024 11.23 Mn
Jun 30, 2024 11.68 Mn
Mar 31, 2024 12.11 Mn
Dec 31, 2023 20.69 Mn
Sep 30, 2023 32.34 Mn
Jun 30, 2023 44.02 Mn
Mar 31, 2023 13.27 Mn
Dec 31, 2022 13.56 Mn
Sep 30, 2022 13.80 Mn
Jun 30, 2022 14.07 Mn
Mar 31, 2022 14.30 Mn
Dec 31, 2021 14.56 Mn
Sep 30, 2021 14.79 Mn
Jun 30, 2021 15.13 Mn
Mar 31, 2021 15.35 Mn
Dec 31, 2020 15.62 Mn
Dec 31, 2017 42,000.00
Sep 30, 2017 47,000.00
Jun 30, 2017 51,000.00